Disease/Infection News

RSS

New data: Quadruple therapy can effectively treat patients with HCV

Exciting new data presented today at the International Liver CongressTM 2011 show that quadruple therapy in chronic hepatitis C patients suppressed the emergence of resistant variants and resulted in a 100% rate of sustained virological response - undetectable HCV RNA - 12 weeks after treatment.

4 Apr 2011

New data finds PegIFN-lambda shows RVR in HCV patients with improved safety, tolerability

Highly exciting new data presented today at the International Liver Congress found Pegylated Interferon-lambda shows superior virological response in HCV patients of genotypes 1-4, with improved safety and tolerability, compared to Pegylated Interferon-alpha, the current standard of care in chronic HCV.

4 Apr 2011

New ‘nanotech’ weapon against drug-resistant superbugs

Scientists at the Institute of Bioengineering and Nanotechnology (IBN) and IBM Research – Almaden have developed the first biodegradable polymer nanoparticles to combat drug-resistant superbugs, such as Methicillin-Resistant Staphylococcus aureus (MRSA). These nanoparticles can selectively kill the bacteria without destroying healthy red blood cells, and being biodegradable, have great potential to treat infectious diseases in the body. This was reported today in the leading scientific journal, Nature Chemistry [(2011) DOI: 10.1038/nchem.1012].

3 Apr 2011

Entry inhibitors can provide first new hepatitis B & D treatments for many years

Promising new viral hepatitis data presented today at the International Liver CongressTM show that entry inhibitors --a new mechanism of action for drugs to treat viral hepatitis -- could provide the first new hepatitis B and hepatitis D treatments for many years.

2 Apr 2011

Experts must monitor new antiviral compounds for HCV treatment

Data presented at the International Liver CongressTM highlight the fact that new novel antiviral compounds for the treatment of hepatitis C virus must be prescribed and monitored by experts and specialists to ensure resistance is minimised.

2 Apr 2011

AHF launches public tribute to Hollywood legend with billboards around Los Angeles

This week, AIDS Healthcare Foundation, the largest global AIDS organization, launched a public tribute to Hollywood legend Elizabeth Taylor with a number of billboards around Los Angeles commemorating her contribution to the AIDS fight.

2 Apr 2011

The Economist examines factors contributing to antimicrobial resistance

"Antibiotic resistance has now become a costly and dangerous problem," The Economist writes in an article examining the factors that have contributed to the global rise of antibiotic resistant bacteria, ahead of next week's World Health Day dedicated to the issue.

2 Apr 2011

Idera's IMO-2125 plus ribavirin Phase 1 trial results against HCV presented at EASL meeting

Idera Pharmaceuticals, Inc. announced today the presentation of data from a four-week Phase 1 clinical trial of IMO-2125 in combination with ribavirin in treatment-naïve patients chronically infected with hepatitis C virus genotype 1.

2 Apr 2011

MSD's Victrelis Phase III trial final results against HCV presented at EASL meeting

MSD reported that final results from a Phase III study of 'Victrelis', its investigational oral hepatitis C protease inhibitor, added to peginterferon alfa-2a marketed by Roche Products Limited, and ribavirin therapy were presented for the first time today as part of a late-breaker poster session at The International Liver Congress / 46th European Association for the Study of the Liver annual meeting.

2 Apr 2011

Boehringer Ingelheim's BI 201335 new data against HCV highlighted at EASL meeting

New data presented today at the International Liver CongressTM 2011, the 46th Annual Meeting of the European Association for the Study of the Liver, in Berlin, highlighted the efficacy of Boehringer Ingelheim's once-daily oral protease inhibitor BI 201335, in both treatment-naïve and -experienced patients with chronic genotype-1 hepatitis C virus infection. Genotype-1 HCV is the most challenging genotype of HCV to treat.

2 Apr 2011

Boehringer Ingelheim advances into Phase 3 clinical trial of BI 201335

Boehringer Ingelheim today announced a preview of the study designs for the pivotal Phase 3 clinical trials evaluating BI 201335, its investigational once-daily oral protease inhibitor, in both treatment-naive and -experienced patients with chronic genotype-1 hepatitis C virus, the most challenging genotype to treat.

2 Apr 2011

Series of new clinical trials confirm range of viable treatment options for HCV patients

Highly anticipated data from a number of clinical trials presented for the first time at the International Liver CongressTM confirmed that a range of new proteases inhibitors will help treat patients who have previously failed therapy for the treatment of chronic hepatitis C.

2 Apr 2011

Recent releases in Global Health

A Lancet Infectious Diseases editorial describes the growing public concerns over a global rise in antimicrobial resistance. "Bearing in mind that our objective is to contain antibiotic resistance rather than eradicate it, several policies could be adopted to help guarantee a future for antibiotics," the editorial states, adding, "We need reliable data to tackle antibiotic resistance.

2 Apr 2011

House subcommittee approves bill calling for report on USAID's efforts to address Haiti's cholera outbreak

The House Foreign Affairs Subcommittee on the Western Hemisphere on Thursday "approved by voice vote a bill (HR 1016) that would require the Obama administration to report to Congress within six months on the handling of U.S. funds for combating a cholera outbreak that occurred after last year's earthquake in Haiti," CQ reports.

2 Apr 2011

Blocking TNF-related apoptosis-inducing ligand pathway partially reconstitutes HBV-specific T cells

A new study presented today at the International Liver Congress shows a novel pathway where activated natural killer (NK) cells expressing death ligands may excessively down-modulate the antiviral immune response in chronic HBV patients.

2 Apr 2011

Encouraging early data from HCV vaccine phase I trial presented at International Liver Congress

Early data from phase I trials of an HCV vaccine presented today at the International Liver CongressTM show encouraging results, with high immunogenicity and good safety profile.

2 Apr 2011

Researcher to host live experiment to show effectiveness of antimicrobial copper in preventing MRSA

Following research by Professor Bill Keevil at the University of Southampton showing that copper can significantly reduce the presence of MRSA, the University, in partnership with the Copper Development Association, is hosting a live experiment that will show the effectiveness of antimicrobial copper in preventing MRSA infections.

2 Apr 2011

South Africa, Lesotho, Swaziland form alliance to fight MDR-TB

Health ministers from Lesotho, Swaziland and South Africa said they have formed an alliance to fight drug-resistant tuberculosis, Deutsche Presse-Agentur/M&C reports.

1 Apr 2011

USAID Administrator testifies before State, Foreign Ops subcommittee about FY12 budget, expresses concerns about FY11 budget cuts

In a hearing regarding the FY12 budget before the House Appropriations State and Foreign Operations subcommittee earlier this week, USAID Administrator Rajiv Shah highlighted the possible impact of the FY11 budget cuts currently being debated in Congress, Foreign Policy's "The Cable" blog reports.

1 Apr 2011

Pediatrician suggests tips to combat allergic symptoms

One of the problems that parents may have during the springtime is deciphering whether their children's sneezing is due to a cold or allergies.

1 Apr 2011

Disease/Infection News

New data: Quadruple therapy can effectively treat patients with HCV

New data finds PegIFN-lambda shows RVR in HCV patients with improved safety, tolerability

New ‘nanotech’ weapon against drug-resistant superbugs

Entry inhibitors can provide first new hepatitis B & D treatments for many years

Experts must monitor new antiviral compounds for HCV treatment

AHF launches public tribute to Hollywood legend with billboards around Los Angeles

The Economist examines factors contributing to antimicrobial resistance

Idera's IMO-2125 plus ribavirin Phase 1 trial results against HCV presented at EASL meeting

MSD's Victrelis Phase III trial final results against HCV presented at EASL meeting

Boehringer Ingelheim's BI 201335 new data against HCV highlighted at EASL meeting

Boehringer Ingelheim advances into Phase 3 clinical trial of BI 201335

Series of new clinical trials confirm range of viable treatment options for HCV patients

Recent releases in Global Health

House subcommittee approves bill calling for report on USAID's efforts to address Haiti's cholera outbreak

Blocking TNF-related apoptosis-inducing ligand pathway partially reconstitutes HBV-specific T cells

Encouraging early data from HCV vaccine phase I trial presented at International Liver Congress

Researcher to host live experiment to show effectiveness of antimicrobial copper in preventing MRSA

South Africa, Lesotho, Swaziland form alliance to fight MDR-TB

USAID Administrator testifies before State, Foreign Ops subcommittee about FY12 budget, expresses concerns about FY11 budget cuts

Pediatrician suggests tips to combat allergic symptoms

How GLP‑1 Agonists Are Shaping the Future of Obesity Treatment With Dr Bryony Henderson

Flow chemistry, AI, and NMR: A next-gen approach to scalable API production

Digital pathology and the PathoVerse: A conversation with Dr. Singh

Latest News